18th Edition (August 5, 2011)
|Diagnostic Criteria for Progressive Multifocal Leukoencephalopathy (PML)|
|Written by G. Firman MD|
|Wednesday, 20 January 2010 04:04|
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by the reactivation of a ubiquitous polyomavirus JC (JCV). PML was for many years a rare disease occurring only in patients with underlying severe impaired immunity.
Over the past three decades, the incidence of PML has significantly increased related to the AIDS (acquired immunodeficiency syndrome) pandemic and, more recently, to the growing use of immunosuppressive drugs. The clinical presentation of PML is variable with neurological symptoms corresponding to affected cerebral areas. Usually, the clinical outcome of patients with PML is poor with an inexorable progression to death within 6 months of symptom onset. Although PML usually requires a brain biopsy or autopsy for confirmation, radiological imaging and a demonstration of JCV-DNA in the CSF (cerebrospinal fluid) provide supportive evidence for the diagnosis. Although there is no proven effective therapy for PML, patients with HIV (human immunodeficiency virus)-related PML may benefit significantly from HAART (highly active antiretroviral therapy).
An independent adjudication committee (IAC) determined that patients whose evaluation fulfilled all three of the following criteria would receive a diagnosis of confirmed PML: progressive clinical disease, MRI findings typical of PML, and detectable JC virus DNA in the cerebrospinal fluid.
Progressive clinical course of disease "clinical vigilance"
Neuroradiologic evidence from MRI or CT
Laboratory detection of JCV DNA or protein in CSF
Created: Jan 20, 2010
Newer news items:
Older news items:
|Last Updated on Friday, 29 August 2014 03:53|
Site Last Modified